Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidance HumanScientific guidelines
Page contentsPage contents Open consultation Related content Topics Keywords: Bioequivalence, generics, tafamidis Open consultation Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidanceDraft: consultation closed Consultation dates: 30/04/2026 to 31/07/2026 Reference Number: EMA/85747/2026 Summary: Comments should be provided using this EU Survey form. For any technical issues, please contact the EUSurvey Support. English (EN) (148.36 KB - PDF)First published: 30/04/2026 View Related content Product-specific bioequivalence guidance Topics Scientific guidelines Share this page